DNA Damage Signaling in Human Cancer Cells
DNA Damage Signaling in Human Cancer Cells
批准号:
7036719
负责人:
FRED BUNZ
金额:
$26.18万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-04-01 至 2008-03-31
关键词:
DNA damageNijmegen breakage syndromebiological signal transductioncarcinogenesiscell cycle proteinscell growth regulationflow cytometryfluorescence microscopyfluorescent in situ hybridizationgene expressiongene targetinggenetic modelsionizing radiationmodel design /developmentneoplasm /cancer therapyprotein kinasetissue /cell culturetumor suppressor genes
中文摘要
描述(申请人提供):许多广泛使用的抗癌药物具有遗传毒性,并激活细胞DNA损伤途径。这些信号转导通路的缺陷是结直肠癌、乳腺癌和其他常见癌症的常见特征,也可以在癌症高发者中遗传。因此,对DNA损伤信号、致癌和癌症治疗之间的关系的研究应该为这些领域的每一个领域提供重要的见解。该项目的目的是开发一个模型系统,用于对人类癌细胞中DNA损伤反应的三个关键调控因子进行遗传评估。
目的1.分析人Chk2蛋白在DNA损伤反应中的作用。最近,人们对Chk2及其在细胞周期调控和癌症易感性中的作用有了大量的了解。这种激酶正常情况下如何调节细胞周期,以及它如何作为肿瘤抑制因子发挥作用的确切细节仍然存在争议。这一目的是为了了解Chk2如何在细胞周期的离散阶段指导受损癌细胞的停滞,以及Chk2功能的丧失如何导致遗传不稳定。
目的2.分析人CHK1在DNA损伤反应中的激活情况。Chk1编码一个规范的细胞周期检查点调节因子,因此是DNA损伤治疗的重要靶点。本研究的目的是研究CHK1的激活作用,CHK1在未受挑战的癌细胞中的作用,以及CHK1和CHK2肿瘤抑制因子的重叠功能。
目的3.DNA损伤信号中NBS1突变的分析。NBS1基因在患有奈梅亨断裂综合征的癌症易感个体中发生突变,代表了人类癌症和DNA损伤信号转导之间的重要联系。这一目的是为了模拟人类癌细胞系中致病的NBS1突变。这样的模型系统将为研究NBS1在细胞周期停滞、染色体断裂修复和治疗敏感性中的功能提供一个独特的机会。
以上研究的结合应能对DNA损伤信号转导通路的功能及其在人类癌症中的功能障碍提供相当深入的认识。
英文摘要
DESCRIPTION (provided by applicant): Many widely used anticancer agents are genotoxic and activate cellular DNA damage pathways. Defects in these signal transduction pathways are frequent features of colorectal, breast, and other common carcinomas, and can also be inherited in cancer-prone individuals. Studies of the relationship between DNA damage signaling, carcinogenesis, and cancer therapy should therefore provide important insights into each of these areas. The aims of this project are to develop a model system for the genetic assessment of three key regulators of the DNA damage response in human cancer cells.
Aim 1. Analysis of human CHK2 kinase in DNA damage responses. Recently a great deal has been learned about CHK2 and its roles in cell cycle regulation and cancer predisposition. The precise details of how this kinase normally regulates the cell cycle, and how it functions as a tumor suppressor remain controversial. This aim is to understand how CHK2 can direct the arrest of damaged cancer cells during discrete phases of the cell cycle, and how loss of CHK2 function might lead to genetic instability.
Aim 2. Analysis of human CHK1 activation in DNA damage responses. CHK1 encodes a canonical cell cycle checkpoint regulator and therefore an important target of DNA damage based therapy. This Aim is intended to study the effects of CHK1 activation, the role of CHK1 in unchallenged cancer cells and the overlapping functions of CHK1 and the CHK2 tumor suppressor.
Aim 3. Analysis of NBS1 mutation in DNA damage signaling. Mutated in cancer prone individuals with the Nijmegen Breakage Syndrome, the NBS1 gene represents an important link between human cancer and the transduction of DNA damage signals. This Aim is to model the pathogenic NBS1 mutations in a human cancer cell line. Such a model system will provide a unique opportunity to study NBS1 function in cell cycle arrest, repair of chromosome breaks and therapeutic sensitivity.
The combination of the above studies should provide considerable insight into functions of DNA damage signal transduction pathways and their dysfunction in human cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Synthetic adenovirus libraries for vector optimization
-
批准号:10460635
-
项目类别:
-
资助金额:$36.84万
-
财政年份:2019
-
负责人:FRED BUNZ
-
依托单位:
Synthetic adenovirus libraries for vector optimization
-
批准号:10188568
-
项目类别:
-
资助金额:$36.84万
-
财政年份:2019
-
负责人:FRED BUNZ
-
依托单位:
Synthetic adenovirus libraries for vector optimization
-
批准号:10021682
-
项目类别:
-
资助金额:$36.84万
-
财政年份:2019
-
负责人:FRED BUNZ
-
依托单位:
A Genetic Model for Early-Onset Breast and Colon Cancer in African Americans
-
批准号:8662394
-
项目类别:
-
资助金额:$30.62万
-
财政年份:2013
-
负责人:FRED BUNZ
-
依托单位:
Summer Translational Oncology Program (STOP)
-
批准号:8865576
-
项目类别:
-
资助金额:$5.22万
-
财政年份:2013
-
负责人:FRED BUNZ
-
依托单位:
A Genetic Model for Early-Onset Breast and Colon Cancer in African Americans
-
批准号:9096071
-
项目类别:
-
资助金额:$28.77万
-
财政年份:2013
-
负责人:FRED BUNZ
-
依托单位:
Summer Translational Oncology Program (STOP)
-
批准号:8413758
-
项目类别:
-
资助金额:$7.51万
-
财政年份:2013
-
负责人:FRED BUNZ
-
依托单位:
A Genetic Model for Early-Onset Breast and Colon Cancer in African Americans
-
批准号:8704891
-
项目类别:
-
资助金额:$28.4万
-
财政年份:2013
-
负责人:FRED BUNZ
-
依托单位:
A Genetic Model for Early-Onset Breast and Colon Cancer in African Americans
-
批准号:8389392
-
项目类别:
-
资助金额:$34.25万
-
财政年份:2012
-
负责人:FRED BUNZ
-
依托单位:
Targeting the ATR pathway in p53-deficient cancers
-
批准号:8300806
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2011
-
负责人:FRED BUNZ
-
依托单位:
Targeting the ATR pathway in p53-deficient cancers
-
批准号:8082529
-
项目类别:
-
资助金额:$34.03万
-
财政年份:2011
-
负责人:FRED BUNZ
-
依托单位:
Targeting the ATR pathway in p53-deficient cancers
-
批准号:8478065
-
项目类别:
-
资助金额:$31.99万
-
财政年份:2011
-
负责人:FRED BUNZ
-
依托单位:
Targeting the ATR pathway in p53-deficient cancers
-
批准号:8676727
-
项目类别:
-
资助金额:$33.01万
-
财政年份:2011
-
负责人:FRED BUNZ
-
依托单位:
Laboratory Training Program in Radiation Oncology
-
批准号:7860662
-
项目类别:
-
资助金额:$10.75万
-
财政年份:2008
-
负责人:FRED BUNZ
-
依托单位:
Laboratory Training Program in Radiation Oncology
-
批准号:8327836
-
项目类别:
-
资助金额:$9.17万
-
财政年份:2008
-
负责人:FRED BUNZ
-
依托单位:
Laboratory Training Program in Radiation Oncology
-
批准号:8100308
-
项目类别:
-
资助金额:$9.92万
-
财政年份:2008
-
负责人:FRED BUNZ
-
依托单位:
CELL IMAGING
-
批准号:7304451
-
项目类别:
-
资助金额:$7.44万
-
财政年份:2006
-
负责人:FRED BUNZ
-
依托单位:
DNA Damage Signaling in Human Cancer Cells
-
批准号:7215233
-
项目类别:
-
资助金额:$25.42万
-
财政年份:2004
-
负责人:FRED BUNZ
-
依托单位:
DNA Damaging Signaling in Human Cancer Cells
-
批准号:6702731
-
项目类别:
-
资助金额:$26.81万
-
财政年份:2004
-
负责人:FRED BUNZ
-
依托单位:
DNA Damaging Signaling in Human Cancer Cells
-
批准号:6880042
-
项目类别:
-
资助金额:$26.81万
-
财政年份:2004
-
负责人:FRED BUNZ
-
依托单位:
海外基金